<ul data-eligibleForWebStory="false"><li>Cipla is gearing up to enter India's weight management sector to compete with Eli Lilly & Co and Novo Nordisk.</li><li>The move is in response to the rising demand for effective obesity solutions in the country.</li><li>Cipla is also strengthening its presence in the central nervous system therapeutic area and plans to enter into niche indications like attention deficit hyperactivity disorder (ADHD) and Parkinson's disease.</li><li>The company aims to evolve its antimicrobial resistance portfolio and continue investing in innovation, strategic alliances, and next-generation therapies.</li></ul>

Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector

Discover more